Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 195-198

  Colomer, R ^a   Alba, E ^b   Gonzalez Martin A ^a   Paz Ares, L ^c   Martin M ^d   Llombart, A ^e   Rodriguez Lescure A ^f   Salvador, J ^g   Albanell, J ^h   Isla, D ⁱ   Lomas, M ^j   Rodriguez C A ^k   Trigo, J M ^b   Germa J R ^l   Bellmunt, J ^h   Tabernero, J ^m   Rosell, R ⁿ   Aranda, E ^o   Cubedo, R ^p   Baselga, J ^m  

^a MD ANDERSON CANCER CENTER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j Allergy Section   (Spain)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l HOSPITAL DURAN I REYNALS   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^o HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^p HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DASATINIB; ERLOTINIB; FLUDARABINE; IMATINIB; LAPATINIB; NAVELBINE; NILOTINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TOPOTECAN;

BLEEDING; CANCER RISK; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHOLESTASIS; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; EDEMA; EDITORIAL; ELECTROLYTE DISTURBANCE; EPISTAXIS; ERYTHEMA; ESOPHAGITIS; GLOSSODYNIA; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY FAILURE; LYMPHOCYTOPENIA; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MUCOSA INFLAMMATION; NEUROPATHY; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT CARE; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PRURITUS; SIDE EFFECT; SKIN DISCOLORATION; SOMNOLENCE; SPAIN; STOMATITIS; TREMOR; VISUAL DISORDER; VOMITING; HEALTH CARE PLANNING; INTERDISCIPLINARY COMMUNICATION; METHODOLOGY; NEOPLASM; ONCOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HEALTH PLANNING GUIDELINES; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NEOPLASMS; SOCIETIES, MEDICAL; SPAIN;

EID: 77951925157     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp595     Document Type: Editorial

References (20)

1. Bajetta E, Gevorgyan A, Mellstedt H. National integration of European standards. Ann Oncol 2007; 18: 969-970.
2. ESMO. Medical Oncology Status in Europe Survey (MOSES). http://www.esmo.org/policy/status-of-medical-oncology-in-europe.html.
3. Hansen HH, Bajorin DF, Muss HB et al. Recommendations for a global core curriculum in Medical Oncology. Ann Oncol 2004; 15: 1603-1612.
4. EMEA. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/htms/human/epar/a.htm.
5. Gralow J, Ozols RF, Bajorin DF et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313-325.
6. Herbst RS, Bajorin DF, Bleiberg H et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 24: 190-205.
7. Ozols RF, Herbst RS, Colson YL et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25: 146-162.
8. Winer E, Gralow J, Diller L et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 812-826.
9. Medicines in Development for Cancer. http://www.phrma.org/medicines_in_ development_for_cancer/.
10. Catania C, Didier F, Leon ME et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005; 92: 265-272.
11. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008; 62: 85-91.
12. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
13. Position. paper by the UKCCCR elderly cancer patients in clinical trials working group. Br J Cancer 2000; 82: 1-3.
14. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923-1925.
15. Estatutos de la Sociedad Española de Oncología Médica (SEOM). http://www.seom.org/seomcms/images/stories/recursos/conoceseom/asociarse/2006/estatutos.pdf.
16. Medical Oncology Training Program. 19086-ORDEN SCO/3370/2006, de 9 de octubre, por la que se aprueba y publica el programa formativo de la especialidad de Oncología Médica. Bol Of Estado 2006; 262: 38122-38129. http://www.msc.es/profesionales/formacion/guiaFormacion.htm.
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
18. Therasse P, Le Cesne A, Van Glabbeke M et al. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 2005; 41: 1426-1430.
19. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-1764.
20. Dhani N, Tu D, Sargent DJ et al. Alternate endpoints for screening phase II studies. Clin Cancer Res 2009.